R C Mercier

Comparison of Neuropsychiatric Side Effects in an Observational Cohort of Efavirenz- and Protease Inhibitor-Treated Patients

Trevor Hawkins, Cindy Geist, Ben Young et al. · HIV Clinical Trials · 2005 · 82 citations · Full text

Medicine, Pharmacology, Psychiatry +16

Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium

R C Mercier, Heather H. Houlihan, Michael J. Rybak · Antimicrobial Agents and Chemotherapy · 1997 · 63 citations · Full text

Medicine, Infectious Diseases, Pharmacology +16

Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model

Heather H. Houlihan, R C Mercier, Michael J. Rybak · Antimicrobial Agents and Chemotherapy · 1997 · 51 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium

R C Mercier, Scott Penzak, Michael J. Rybak · Antimicrobial Agents and Chemotherapy · 1997 · 35 citations · Full text

Life Sciences, Microbiology, Pharmacology +16

Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model

Michael J. Rybak, Heather H. Houlihan, R C Mercier et al. · Antimicrobial Agents and Chemotherapy · 1997 · 16 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17